CM
CMPX icon

Caption Management’s Compass Therapeutics CMPX Stock Holding History

Caption Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-154,170
Closed -$540K – 1632
2025
Q3 		$540K Sell
154,170
-571,340
-79% -$1.8M ﹤0.01% 1286
2025
Q2 		$1.89M Buy
+725,510
New +$1.5M 0.02% 735

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caption Management's CMPX Position: Q4 2025 in Review

Caption Management sold out of Compass Therapeutics (CMPX) in Q4 2025, closing a stake of 154,170 shares — an estimated $540K sold.

Caption Management first reported a position in CMPX in Q2 2025 and held it in 2 quarters. The position peaked at $1.89M in Q2 2025. 173 funds tracked by Wall St. Rank hold CMPX as of Q4 2025.

  • Caption Management reported no remaining Compass Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Caption Management sold 154,170 Compass Therapeutics shares in Q4 2025, an estimated $540K.
  • Caption Management first reported a position in Compass Therapeutics in Q2 2025 and held it in 2 quarters.
  • Caption Management's Compass Therapeutics position peaked at $1.89M in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Compass Therapeutics as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.